Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503533 | 0.79 | MAT2A (0.34) | MAT2ABRD4IDO1LRRK2 | |
| SCHEMBL12889638 | 0.79 | MAT2A (0.34) | MAT2ABRD4IDO1LRRK2 | |
| SCHEMBL30503542 | 0.78 | MAT2A (0.33) | MAT2AIDO1LRRK2 | |
| SCHEMBL26631307 | 0.78 | MAT2A (0.33) | MAT2AIDO1LRRK2 | |
| SCHEMBL24323859 | 0.74 | CCR1 (0.37) | HASPINMTNR1AMTNR1BBRD4 | |
| SCHEMBL30503618 | 0.74 | LRRK2 (0.47) | MAT2ALRRK2 | |
| SCHEMBL29601076 | 0.74 | CCR1 (0.37) | HASPINMTNR1AMTNR1BBRD4 | |
| SCHEMBL25169082 | 0.74 | ALDH1A1 (0.45) | MAT2A | |
| SCHEMBL23742486 | 0.74 | MAT2A (0.32) | MAT2A | |
| SCHEMBL31525660 | 0.74 | CDK7 (0.36) | HASPINMTNR1AMTNR1BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| WO-2019233438-A1 | KINASE SELECTIVE INHIBITOR | 北京大学深圳研究生院 (CN) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | HASPIN 2891/4885MAT2A 4489/4885MTNR1A 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.